Zealand Pharma sends blood sugar drug to US market

The hypoglycemia treatment Zegalogue is now available on the US market, Zealand Pharma reported on Thursday. Three months ago, the US FDA approved the drug for treating very low blood sugar in patients with diabetes.
Photo: Zealand Pharma / PR
Photo: Zealand Pharma / PR

Three months after the US Food and Drug Administration authorized Zealand Pharma's drug for severe hypoglycemia, the Danish biotech firm is sending this treatment to the US market.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading